| Literature DB >> 36203165 |
Emily Aldridge1,2,3, Maleesa Pathirana4,5, Melanie Wittwer4,6, Susan Sierp6, Shalem Y Leemaqz7, Claire T Roberts4,5,7, Gustaaf A Dekker4,5,8, Margaret A Arstall4,6.
Abstract
AIM: Maternal complications of pregnancy, including hypertensive disorders of pregnancy, gestational diabetes mellitus, intrauterine growth restriction, preterm labour, and placental abruption, are associated with increased risk of future cardiometabolic disease. Lifestyle interventions that focus on preventative strategies for this young, high-risk population of women may assist in cardiometabolic disease risk reduction. The aim of this preliminary registry analysis was to observe the change in maternal metabolic syndrome status after receiving a nurse practitioner-led lifestyle intervention delivered soon after a complicated pregnancy.Entities:
Keywords: Cardiovascular disease prevention; Maternal health; Metabolic syndrome; Pregnancy complications
Year: 2022 PMID: 36203165 PMCID: PMC9535230 DOI: 10.1186/s13098-022-00916-8
Source DB: PubMed Journal: Diabetol Metab Syndr ISSN: 1758-5996 Impact factor: 5.395
Fig. 1Study inclusion flow-chart
Participant demographics at baseline (6 months postpartum), n = 64
| Participant characteristics | Mean ± standard deviation, or |
|---|---|
| Age, years | 33.08 ± 5.75 |
| Gravidity | 2.80 ± 1.65 |
| Parity | 2.20 ± 1.34 |
| Index pregnancy booking BMI, kg/m2 | 29.04 ± 7.00 |
| SEIFA IRSAD | 922.56 ± 57.50 |
| White | 35 (54.7) |
| Referring pregnancy complication | |
| HDP | 24 (37.5) |
| GDM | 44 (68.8) |
| IUGR | 5 (7.8) |
| PTL | 0 |
| PA | 0 |
| Required interpreter | 12 (18.8) |
| Marital status | |
| Married | 44 (68.8) |
| De facto | 14 (21.9) |
| Separated | 1 (1.6) |
| Single | 5 (7.8) |
| Employment | |
| Unemployed | 28 (43.8) |
| Maternity leave | 16 (25.0) |
| Casual | 10 (15.6) |
| Part-time | 9 (14.1) |
| Full-time | 1 (1.6) |
| Medicated hypertension | 4 (6.3) |
| T1DM | 2 (3.1) |
| T2DM | 1 (1.6) |
| Current smoking | 6 (9.4) |
| Current illicit drug use | 1 (1.6) |
BMI body mass index, SEIFA IRSAD Socioeconomic Index for Area Index of Relative Socioeconomic Advantage and Disadvantage, HDP hypertensive disorders of pregnancy, GDM gestational diabetes mellitus, IUGR intrauterine growth restriction, PTL preterm labour, PA placental abruption, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus
Metabolic syndrome status and risk factors at baseline and review, n = 64
| Baseline | Review | p-value | |
|---|---|---|---|
| Metabolic syndrome present, n (%) | 22 (34.4) | 19 (29.7) | 0.58 |
| Number of metabolic syndrome criteria present | |||
| 0 | 6 (9.4) | 7 (10.9) | |
| 1 | 16 (25.0) | 16 (25.0) | |
| 2 | 19 (29.7) | 22 (34.4) | |
| 3 | 14 (21.9) | 11 (17.2) | |
| 4 | 8 (12.5) | 7 (10.9) | |
| 5 | 0 (0) | 1 (1.6) | |
| BMI, kg/m2 | 30.27 ± 7.09 | 30.40 ± 7.38 | 0.31 |
| Waist circumference, cm | 95.24 ± 14.99 | 95.11 ± 14.56 | 0.23 |
| Peripheral SBP, mmHg | 122.22 ± 13.12 | 120.97 ± 12.73 | 0.11 |
| Peripheral DBP, mmHg | 73.09 ± 10.57 | 73.11 ± 11.67 | 0.49 |
| Triglycerides, mmol/L | 1.37 ± 0.93 | 1.27 ± 0.71 | 0.18 |
| HDL cholesterol, mmol/L | 1.28 ± 0.28 | 1.25 ± 0.30 | 0.18 |
| Glucose, mmol/L | 5.20 ± 1.20 | 5.15 ± 0.77 | 0.44 |
| Insulin, mU/L | 15.22 ± 15.54 | 12.22 ± 7.69 | 0.09 |
| HOMA-IR | 3.54 ± 3.72 | 2.84 ± 1.99 | 0.24 |
| Medicated hypertension | 4 (6.3) | 6 (9.4) | |
| Medicated T2DM | 1 (1.6) | 2 (3.1) | |
| Current smoking | 6 (9.4) | 5 (7.8) | |
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, HOMA-IR Homeostatic Model Assessment for Insulin Resistance, T2DM type 2 diabetes mellitus
Mean change in cardiometabolic risk factors over time
| No MetS at either time point, n = 37 | MetS at first timepoint, no MetS at second timepoint (MetS resolved), n = 8 | No MetS at either timepoint, n = 14 | Developed MetS during study: | |
|---|---|---|---|---|
| BMI, kg/m2 | 0.31 ± 2.40 | − 0.87 ± 2.63 | 0.29 ± 1.49 | 0.08 ± 1.42 |
| Waist circumference, cm | − 0.21 ± 12.88 | − 3.71 ± 4.22 | 0.39 ± 5.52 | − 0.02 ± 2.94 |
| Peripheral SBP, mmHg | − 4.57 ± 19.90 | − 3.12 ± 8.22 | − 1.64 ± 11.00 | 3.20 ± 6.65 |
| Peripheral DBP, mmHg | − 2.54 ± 14.67 | − 1.38 ± 9.97 | 1.21 ± 8.67 | 3.20 ± 9.26 |
| Triglycerides, mmol/L | − 0.09 ± 0.78 | − 0.45 ± 0.67 | 0.12 ± 0.77 | 0.32 ± 0.25 |
| HDL cholesterol, mmol/L | 0.54 ± 0.41 | 0.10 ± 0.19 | − 0.50 ± 0.13 | 0.40 ± 0.27 |
| Glucose, mmol/L | 0.22 ± 1.97 | − 0.20 ± 1.21 | 0.41 ± 1.80 | 0.44 ± 0.89 |
| Insulin, mU/L | − 1.44 ± 16.16 | − 12.58 ± 16.44 | 1.10 ± 10.69 | − 0.42 ± 8.26 |
| HOMA-IR | − 0.39 ± 3.66 | − 3.26 ± 5.02 | 0.34 ± 3.56 | 0.15 ± 2.32 |
Data are presented as mean ± standard deviation. ‘Improve’ denotes those who had MetS at the first time point but did not meet the criteria at the second time point. ‘No change’ denotes those who had MetS at both time points. ‘Worse’ denotes those who did not have MetS at the first time point but met the criteria at the second timepoint
MetS metabolic syndrome, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HDL high-density lipoprotein, HOMA-IR Homeostatic Model Assessment for Insulin Resistance